公开(公告)号：US20190025308A1

公开(公告)日：2019-01-24

申请号：US16041363

申请日：2018-07-20

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Craig Anthony CUMMINGS ,  Yan LI ,  Sarah Margaret PAUL ,  Erica Beth SCHLEIFMAN ,  David SHAMES ,  David FABRIZIO ,  Daniel LIEBER ,  Geoffrey Alan OTTO ,  Mark KENNEDY ,  Travis CLARK ,  Doron LIPSON ,  Jie HE ,  Shan ZHONG

IPC: G01N33/574 ,  C07K16/28 ,  G16H50/70 ,  G16H50/50 ,  G16H50/30 ,  G16H50/20 ,  G06F17/30 ,  C07K14/735 ,  A61P35/00

Abstract: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

公开(公告)号：US20220412981A1

公开(公告)日：2022-12-29

申请号：US17686565

申请日：2022-03-04

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： David FABRIZIO ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Marcin KOWANETZ ,  David SHAMES ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY ,  Wei ZOU

IPC: G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US20240288430A1

公开(公告)日：2024-08-29

申请号：US18513107

申请日：2023-11-17

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Craig Anthony CUMMINGS ,  Yan LI ,  Sarah Margaret SHAGAN ,  Erica Beth SCHLEIFMAN ,  David SHAMES ,  David FABRIZIO ,  Daniel LIEBER ,  Geoffrey Alan OTTO ,  Mark KENNEDY ,  Travis CLARK ,  Doron LIPSON ,  Jie HE ,  Shan ZHONG

IPC: G01N33/574 ,  A61K39/00 ,  A61P35/00 ,  C07K14/735 ,  C07K16/28 ,  C12Q1/68 ,  C12Q1/6883 ,  G06F16/28 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70

CPC classification number: G01N33/574 ,  A61P35/00 ,  C07K14/70535 ,  C07K16/2827 ,  C07K16/2896 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/57492 ,  G06F16/285 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C12Q2600/156 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

公开(公告)号：US20170183740A1

公开(公告)日：2017-06-29

申请号：US15272283

申请日：2016-09-21

Applicant: Genentech, Inc.

Inventor： Wei YU ,  David SHAMES ,  Hartmut KOEPPEN ,  See PHAN ,  Sandra ROST

IPC: C12Q1/68 ,  C07K16/22 ,  C07K16/28

CPC classification number: C12Q1/6886 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q2600/158

Abstract: The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.